Thomas B. Okarma, PhD, MD., has left as GERN’s President, CEO and Director but, will remain as a consultant.
- David L. Greenwood, CFO, becomes President, interim CEO and a member of the BOD. Hoyoung Huh, M.D., Ph.D., a director, becomes Executive Chairman. Alexander E. Barkas, Ph.D., chairman of the board moves to the role of lead independent director. David has also served as GERN’s EVP and continues to serve as CFO;
- As GERN’s Executive Chairman, Dr. Huh brings substantial biotechnology and pharmaceutical business and product development experience across therapeutic areas. He is chairman of the board of directors of BiPar Sciences, Inc., a wholly-owned subsidiary of Sanofi-Aventis, and serves on the boards of several privately held companies. He was previously a member of the board of directors, COO, and head of the PEGylation business unit at Nektar Therapeutics and was a partner at McKinsey & Company.
The Bottom Line: This new leadership structure reflects GERN’s progression into mid-stage clinical development of multiple therapeutic product candidates and its objective is to intensify the development programs and clinical trials? GERN’s stock has traded up $0.06 or 1.20% at the markets open.